The QualityStocks Daily Friday, May 31st, 2019

Today's Top 3 Investment Newsletters

StockMarketWatch (SBOT) +62.50%

Penny Stock 101 (GTEH) +51.13%

TopPennyStockMovers (TMRC) +37.12%

The QualityStocks Daily Stock List

Chemesis International, Inc. (CADMF)

Green Stock Report, Marketbeat, Small Caps Daily, Stockwatch, The Trading Letter, Financial Buzz, Midas Letter, Business Insider, Trading View, Insider Financial, CannabisMarketCap, CannabisFN, OTC Markets, InvestorsHub, Tip Ranks, Market Screener, Stockhouse, GlobeNewswire, Technical420, Investing News, Dividend Investor, and Insider Tracking reported previously on Chemesis International, Inc. (CADMF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Currently operating within California, Puerto Rico, and Colombia, Chemesis International, Inc. is a vertically integrated global leader in the cannabis industry. It is developing a strong presence in important markets. This is from cultivation, to manufacturing, distribution and retail. Chemesis International lists on the OTCQB and the Company is based in Vancouver, British Columbia.

Chemesis International has started the process to expand its operations into the Central U.S. It will concentrate on establishing operations in Michigan, Wisconsin, Missouri, and Illinois. It is in the application stage in each State. Furthermore, it is in the process of completing due diligence on assets, which include cultivation, extraction, and distribution.

Chemesis International has facilities in Puerto Rico and California, allowing for the cost effective production and distribution of its products. In addition, it leverages exclusive brands and partnerships. Chemesis also uses the highest quality extraction methods to provide consumers with quality cannabis products. With it’s worldwide reach and exclusive partnerships, the Company is working to establish and grow new markets internationally. Chemesis has current operations underway in Puerto Rico with Natural Ventures, in Colombia with La Finca, and in California with California Sap and Desert Zen.

The Company has its state-of-the-art grow facility in Puerto Rico that highlights a 2,000-plus grow light capacity and a 30,000-plus lb overall grow capacity. Moreover, La Finca brings more than 1,000 acres of land for cultivation in Colombia. Chemesis has over 2,000 relationships with farming families that make up its land package.

Regarding Retail Sales, Chemesis is presently retailing exclusive products in Puerto Rico and engaging retail storefronts in the California market. Additionally, it is working to open exclusively branded shops in manifold markets. It distributes and transports California Sap, Jay and Silent Bob’s Private Stash, and 3rd party brands to more than 600 dispensaries in California and Puerto Rico.

Concerning Manufacturing, Chemesis International is able to offer it’s clients all types of extractions, formulations and products, specializing in BHO Extraction, Alchohol Extraction, and CO2 Extraction. Currently, the Company has the capacity to process greater than 2,000 lbs of raw material daily.

Pertaining to Distribution, Chemesis International’s Desert Zen currently has a major presence in Southern California. The Company has a fleet of fully compliant vehicles that are servicing the State.

This week, Chemesis International wholly-owned subsidiary La Finca Interacviva-Arachna Med SAS announced it received notification from the Ministry of Justice, that is has received approval for three new cultivation licenses for three additional farms near Bogota, Colombia. At present, the Company has 5 acres planted for its pilot spring harvest. It can expand to more than 100 acres once the initial harvest is complete. These new acres, to be planted shortly, will be focused on producing biomass and will also contribute in expediting the expansion of La Finca’s seed stock, a vital step in guaranteeing acreage growth is in sync with seed availability.

Chemesis International, Inc. (CADMF), closed Friday's trading session at $1.34, even for the day, on 211,811 volume with 292 trades. The average volume for the last 3 months is 207,208 and the stock's 52-week low/high is $0.20/$1.72.


NervGen Pharma Corp. (NGENF)

Penny Stock Hub, Investor Ideas, Stockhouse, Stock Target Advisor, Stockwatch, PressReader, and Investorx reported previously on NervGen Pharma Corp. (NGENF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

NervGen Pharma Corp. is a regenerative medicine company based in Vancouver, British Columbia. Its commitment is to creating innovative solutions for the treatment of nerve damage. This includes spinal cord and peripheral nerve injury. In addition, NervGen continues to research secondary applications, including multiple sclerosis (MS), stroke, acute myocardial infarction induced arrhythmia (AMI, commonly known as a heart attack) and other neurodegenerative diseases. The Company’s lead compound is NVG-291. NervGen Pharma lists on the OTC Markets Group’s OTCQB.

The Company’s plan is to initiate a Phase 1 human clinical trial for its lead compound, NVG-291, in early 2020 under an Investigational New Drug application with the US Food and Drug Administration (FDA). NervGen is advancing NVG-291 for the treatment of spinal cord injury as it believes this indication is a major opportunity because of the present lack of non-surgical solutions in the market, the dramatic impact on quality of life, and the high cost burden to the healthcare system. NervGen believes NVG-291 as a therapy could alleviate or improve upon the symptoms and conditions associated with spinal cord injury and enable these patients to live more active and productive lives.

NervGen Pharma’s core technology targets protein tyrosine phosphatase sigma (PTPσ), a neural receptor that impedes nerve regeneration. Inhibition of the PTPσ receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for different medical conditions.

Yesterday, NervGen Pharma announced that it appointed Denis Bosc, PhD, as the Company's Vice President, Chemistry, Manufacturing and Control (CMC). Mr. Paul Brennan has also joined the NervGen Pharma team to advise on strategy and business development.

Dr. Bosc has a demonstrated history of working with an array of drug substance and drug product CDMOs for programs at varied stages of pharmaceutical development, including preclinical to commercial products. Mr. Brennan started his pharmaceutical business development career as the Director of Global Licensing at Astra (now part of AstraZeneca). There, he was responsible for product licensing, technology evaluation and acquisitions in the respiratory and inflammatory diseases area.

NervGen Pharma Corp. (NGENF), closed Friday's trading session at $1.14828, up 1.62%, on 1,300 volume with 2 trades. The average volume for the last 3 months is 13,214 and the stock's 52-week low/high is $1.092/$1.525.


Argonaut Gold, Inc. (ARNGF)

Micro Small Cap, Stockhouse, TipRanks, StockScores, StockInvest, Stock Guru, Stock Target Advisor, Marketbeat, Market Screener, Invest Tribune, and Mining Stock Valuator reported earlier on Argonaut Gold, Inc. (ARNGF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Argonaut Gold, Inc. engages in exploration, mine development and production activities. The Company’s main assets are the production stage El Castillo mine and San Agustin mine that together form the El Castillo Complex in Durango, Mexico. Main assets also include the production stage La Colorada mine in Sonora, Mexico. Argonaut Gold has its corporate office in Reno, Nevada.

The Company’s advanced exploration stage projects include the San Antonio project in Baja California Sur, Mexico, the Cerro del Gallo project in Guanajuato, Mexico and the Magino project in Ontario, Canada. In addition, Argonaut Gold has a number of exploration stage projects, all of which are located in North America.

This year, Argonaut Gold expects to produce more than 200,000 GEOs (gold equivalent ounces) annually from its existing operations. This would reflect greater than 65 percent production growth from 2017 through 2019. This production growth is chiefly driven by the ramp up of the El Castillo Complex with the addition of San Agustin and the extension of mine life at El Castillo subsequent to the San Juan concession purchase from Fresnillo Plc, and also higher anticipated grades at La Colorada as mining transitions to the El Creston pit.

Argonaut Gold expects it will produce between 200,000 to 215,000 GEOs during 2019 at a cash cost of between $775 to $875 per gold ounce sold and all-in sustaining costs (AISC) of between $975 to $1,075 per gold ounce sold. The Company has a nine year track record of profitable mining.

Recently, Argonaut Gold announced its operating and financial results for Q1 ended March 31, 2019. The Company reported record quarterly production of 54,169 gold equivalent ounces (GEO or GEOs), a quarterly net cash increase of $11.7 million, cash flow from operating activities before changes in operating working capital of $18.0 million, net income of $4.1 million or earnings per share of $0.02, adjusted net income of $2.4 million or adjusted earnings per share of $0.01.

Mr. Pete Dougherty, Argonaut Gold President and Chief Executive Officer, stated, "We challenged ourselves to grow our production approximately 65 percent from 2017 to 2019. With a second consecutive quarter of record production above 50,000 GEOs, we are well on our way to achieving this goal with an annualized production profile of over 200,000 GEOs per annum…”

Argonaut Gold, Inc. (ARNGF), closed Friday's trading session at $1.238, up 2.31%, on 23,105 volume with 22 trades. The average volume for the last 3 months is 21,860 and the stock's 52-week low/high is $0.852/$1.86.


Cryo-Cell International, Inc. (CCEL)

Zacks, Stockwatch, Street Insider, StockInvest, Morningstar, Marketbeat, Stockhouse, and Wallmine reported earlier on Cryo-Cell International, Inc. (CCEL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Markets, Cryo-Cell International, Inc. is the world’s first private cord blood bank. In 1992, it was the first private cord blood bank to separate and store stem cells. In addition to its family bank, Cryo-Cell International has a public banking program in partnership with Duke University. The Company’s public bank has provided cord blood for greater than 600 transplantations and operates cord blood donation sites throughout the U.S in prominent hospitals. Established in 1989, Cryo-Cell International has its head office in Oldsmar, Florida.

The Company’s mission is to provide clients with state-of-the-art cord blood and cord tissue cryopreservation services. In addition, its mission is to raise awareness of the opportunity for expectant parents to bank or donate their baby’s cord blood and support the advancement of regenerative medicine.

Cryo-Cell International operates in a facility that is FDA registered, cGMP-/cGTP-compliant and licensed in all States requiring licensure. It is AABB accredited as a cord blood facility. Moreover, Cryo-Cell was the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the strictest cord blood quality standards set by any globally recognized, independent accrediting organization. Cryo-Cell is also ISO 13485:2003–certified by TÜV, an internationally recognized, quality assessment organization.

In the Cryo-Cell laboratory, only qualified technologists handle specimens. Furthermore, the specimens are individually processed using the industry’s gold standard method to maximize the recovery of stem cells. Cryo-Cell International holds an interest in more cord blood patents than any other cord blood bank via its equity position in Saneron CCEL Therapeutics (Saneron), a University of South Florida spin-out biotechnology company. Saneron’s commitment is to advancing research using readily available, non-controversial cord blood stem cells.

Recently, Cryo-Cell International announced results for the fiscal first quarter ended February 28, 2019. Consolidated Revenues for Q1 of fiscal 2019 were $7.50 million versus $6.23 million for Q1 of fiscal 2018. This represents a 20 percent increase. Cryo-Cell reported Net Income of $276,000 or $0.04 per basic common share and $0.03 per diluted common share for the three months ended February 28, 2019 versus a Net Loss of roughly $2.53 million, or $0.36 per basic and diluted common share for the same period in 2018.

Cryo-Cell International, Inc. (CCEL), closed Friday's trading session at $7.70, up 2.12%, on 3,700 volume with 6 trades. The average volume for the last 3 months is 1,476 and the stock's 52-week low/high is $5.50/$9.30.


Galaxy Gaming, Inc. (GLXZ)

Micro Small Cap, Zacks, Marketbeat, Stockhouse, StockInvest, Stockwatch, and Capital Cube reported previously on Galaxy Gaming, Inc. (GLXZ), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Galaxy Gaming, Inc. is a developer and distributor of casino table games and enhanced systems. The Company develops, manufactures, and distributes unique proprietary table games, state-of-the-art electronic wagering platforms and enhanced bonusing systems. These are for land-based, riverboat, cruise ships and online casinos around the world. Galaxy Gaming has its corporate office in Las Vegas, Nevada.

The proprietary products are marketed to the above-mentioned entities to enhance their gaming floor operations and improve profitability, productivity and security. This is while offering popular innovative gaming entertainment content and technology to their players. Game concepts and intellectual property (IP) associated with the games are normally protected by patents, trademarks and copyrights.

Galaxy Gaming sell its products mainly through its internal sales force. The products are sold to casinos throughout North America, the Caribbean, the British Isles, Europe, Africa and to cruise ships and internet gaming sites globally.

This month, Galaxy Gaming announced that it received its Manufacturer’s licensing approval from the Alcohol and Gaming Commission of Ontario (AGCO). In addition, the Company announced this month that it received its Manufacturer’s licensing approval from the Maryland Lottery and Gaming Control Agency.

On May 29, 2019, Galaxy Gaming announced that it received an Order granting its Gaming Related Contractor Certificate from the State of Wisconsin, Division of Gaming.

Mr. Todd Cravens, Galaxy Gaming’s President and Chief Executive Officer, said, “As we have promised to our clients, shareholders and employees, Galaxy continues to receive new gaming licenses, and today is no exception. I am extremely pleased to announce Galaxy has received an Order granting its Gaming Related Contractor Certificate in the State of Wisconsin. This newest license provides us the great opportunity to bring our felt and progressive products to Wisconsin. As we continue to move forward from the structural change we made May 6, 2019, we appreciate Wisconsin embracing our bright future and awarding Galaxy its Gaming Related Contractor Certificate.”

Galaxy Gaming, Inc. (GLXZ), closed Friday's trading session at $1.84, up 6.36%, on 8,030 volume with 10 trades. The average volume for the last 3 months is 20,568 and the stock's 52-week low/high is $1.05/$2.20.


Gold Reserve, Inc. (GDRZF)

Junior Mining Network, The OTC Reporter, Zacks, Marketbeat, Stockhouse, TipRanks, Stockwatch, Emerging Growth, Capital Equity Review, and Wallet Investor reported previously on Gold Reserve, Inc. (GDRZF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQX-listed, Gold Reserve, Inc. acquires, explores, and develops mineral properties. The Company has a history in mining dating back to 1956. It was originally established for the purpose of acquiring, exploring, and developing mining properties and placing them into production. Gold Reserve is headquartered in Spokane, Washington.

In 1992, Gold Reserve acquired and began developing what is now known as the Brisas gold and copper project in the historic Km 88 mining district of the State of Bolivar in southeastern Venezuela (Brisas Project). From 1992 to 2009, Gold Reserve invested almost US $300 million in acquisition, land exploration, development, equipment, and engineering costs.

In April 2008, Venezuela revoked the previous authorization to proceed with construction of the Brisas Project. Therefore, in October 2009, Gold Reserve filed a Request for Arbitration under the Additional Facility Rules of the International Centre for Settlement of Investment Disputes (ICSID) of the World Bank, in Washington D.C., against Venezuela seeking compensation for the losses caused to Gold Reserve by Venezuela’s violations of the Agreement between the Government of Canada and the Government of the Republic of Venezuela for the Promotion and Protection of Investments (Canada-Venezuela Treaty) concerning the Company and its investments in Venezuela.

In June of 2017, Gold Reserve signed a settlement agreement (as amended) with Venezuela. As of August 31, 2018, Venezuela had deposited roughly $187.5 million to the Trust Account.

In August of 2016, Gold Reserve executed an agreement with the government of Venezuela to form a jointly owned company. In October of 2016, together with an affiliate of the government of Venezuela, Gold Reserve formed Empresa Mixta Ecosocialista Siembra Minera, S.A., the entity whose purpose is to develop the Siembra Minera Project.

In May of 2018, Siembra Minera obtained the Permit to Effect for the Siembra Minera Project from the Venezuelan Ministry of the Environment. It later participated in an inauguration ceremony to mark the formal commencement of activities on the Siembra Minera Project now that the Environmental Permit to Effect has been issued. Siembra Minera is now awaiting the issuance of the Initiation Act authorizing it to proceed with work on the Project.


Gold Reserve, Inc. (GDRZF), closed Friday's trading session at $2.54, up 3.67%, on 32,187 volume with 14 trades. The average volume for the last 3 months is 6,659 and the stock's 52-week low/high is $1.84/$3.02.


Predictive Technology Group, Inc. (PRED)

NetworkNewsWire, Zacks, StreetWise Reports, pm360, Dividend Investor, Equity Clock, Wallet Investor, Investors Hangout, Business Insider, 4-Traders, Simply Wall St, OTC Markets, Insider Tracking, Market Screener, Proactive Investors, InvestorsHub, Insider Financial, Stockhouse, Wallmine, and Infront Analytics reported previously on Predictive Technology Group, Inc. (PRED), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Predictive Technology Group, Inc. is a leader in the use of data analytics for disease identification and subsequent therapeutic intervention via precision therapeutic treatments. Its aim is to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. Predictive Technology Group is based in Salt Lake City, Utah.

The Company’s subsidiaries focus on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. These subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.

Predictive Technology works to advance regenerative medicine. Its dedication is also to assisting women in overcoming the devastating consequences of endometriosis by way of appropriate early-stage diagnosis and subsequent treatment. Predictive Biotech, Inc., a Salt Lake City life sciences company, is a leader in human cell and tissue products for use in regenerative medicine. An increasing national network of clinics, health systems, researchers and physicians take advantage of Predictive’s four main placental-derived and Wharton’s jelly umbilical cord-derived products.

Predictive Laboratories concentrates on clinical and discovery work for human infertility and genetic conditions affecting women and children. This includes endometriosis, scoliosis and degenerative disc disease. Testing is performed using state-of-the-art instrumentation at its CAP and CLIA accredited facility.

Predictive Technology recently completed the acquisition of Taueret Laboratories, LLC, a clinical and research molecular laboratory. Taueret Laboratories will join Predictive Technology Group’s newest subsidiary Predictive Laboratories. In addition, Predictive Technology Group has completed the buildout of a new production laboratory and research and development (R&D) facility for its subsidiary company, Predictive Biotech. The newly renovated 22,000 square foot facility, located in Research Park on the University of Utah’s campus, features an ISO 7 cleanroom and 18 ISO 5 production hoods.

This month, Predictive Technology Group announced the signing of a Letter of Intent (LOI) with IQVIA (Formerly Quintiles and IMS) to guide the regulatory strategy for its wholly-owned subsidiary Predictive Biotech. The collaboration will hasten the process of identifying and executing the appropriate regulatory pathways for the Company’s existing products and future product candidates.

IQVIA will guide Predictive Biotech in its U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application and subsequent clinical trial for osteoarthritis (OA) of the knee. Predictive Biotech expects to meet with the FDA during Q3 of 2019 to discuss the submission of the IND with the goal of determining the safety and effectiveness of CoreCyte™ compared to a placebo control for treatment of OA of the knee.

Predictive Technology Group, Inc. (PRED), closed Friday's trading session at $4.09, up 5.68%, on 187,216 volume with 400 trades. The average volume for the last 3 months is 309,682 and the stock's 52-week low/high is $0.769/$4.75.


International Land Alliance, Inc. (ILAL)

OTC Markets, InvestorsHub, Simply Wall St, Investors Hangout, Morningstar, The Street, Trading View, and Market Screener reported previously on International Land Alliance, Inc. (ILAL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

International Land Alliance, Inc. concentrates on the development, construction, and marketing of properties. The Company’s inventory includes properties that are residential, commercial, recreational, waterfront, ranch, hotel, and marina. International Land Alliance’s shares trade on the OTC Markets Group’s OTCQB. Established in 2013, the Company has its corporate headquarters in San Diego, California.

International Land Alliance’s intention is to construct and develop resort properties, and other commercial properties, and also residential communities to home buyers, retirees, investors, and commercial developers. The Company’s main goal is to sell desirable properties, at competitive prices, with favorable financing options for individual purchases and/or bulk purchases suitable for all kinds of investors and buyers.

International Land Alliance offers the option of financing with a guaranteed acceptance on any purchase for every customer. The Company removes the middleman. As such, loans are approved directly by International Land Alliance providing easy and affordable financing terms. Moreover, there are no prepayment penalties, credit or background checks, and extremely competitively low interest rates.

The Company’s developments include Oasis Park Resort; Valle Divino Resort; and Villas Del Enologo (Vintners Villas) at Rancho Tecate. Oasis Park Resort (San Felipe – Puertecitos Corridor Northern Baja California, Mexico) is a 497 acre master planned real estate community just south of San Felipe. It is undergoing development as an ecotourism, green community to coincide with the natural amenities Baja California provides. There are 1,344 residential home sites that are roughly 1/4-acre each.

Valle Divino Resort consists of 123 residential lots and 3 commercial lots comprising a total of 20 acres in Ensenada, Baja, Mexico. Villas Del Enologo at Rancho Tecate is a 2.6 acre parcel within the prestigious Rancho Tecate. It is a planned 24 – 2B/2B Vineyard Villas with private wine cellar.

The Second Phase will include an additional 22 Vineyard Villas. The Rancho Tecate Resort is a 1,500-acre master planned resort in Tecate, Baja California, situated 7 miles south of the U.S.-Mexico Border and just north of the Guadalupe Valley, the premier wine region in all of Mexico. The Rancho Tecate Resort includes 1,400 home sites, a renowned restaurant, a hotel with conference facilities, and equestrian – all surrounding a verdant vineyard landscape.

International Land Alliance, Inc. (ILAL), closed Friday's trading session at $2.01, up 0.50%, on 700 volume with 2 trades. The average volume for the last 3 months is 998 and the stock's 52-week low/high is $0.50/$5.00.


Research Solutions, Inc. (RSSS)

NetworkNewsWire, Penny Stock Tweets, InvestorsHub, Seeking Alpha, MarketWatch, Simply Wall St, Investor Point, Nasdaq, Street Insider, OTC Markets, Wall Street Resources, Morningstar, Zacks, Stockhouse, Marketbeat and PR Newswire reported previously on Research Solutions, Inc. (RSSS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

Research Solutions, Inc. is an innovator in providing cloud-based solutions for scientific research. The Company is a pioneer in cloud-based SaaS (Software-as-a-Service) research intelligence products and services for research-intensive organizations. Research Solutions has its wholly-owned subsidiary Reprints Desk, Inc. OTCQB-listed, Research Solutions is based in Encino, California.

The Company’s cloud-based SaaS platform provides customers with on demand access to, and augmented data from, tens of millions of scientific, medical, and technical (STM) documents. This is in addition to tens of millions of articles previously published.

The above-mentioned Reprints Desk improves how journal articles and clinical reprints are accessed, procured, and legally used in evidence-based promotions, medical affairs, and scientific, technical, and medical (STM) research. Reprints Desk and Altmetric LLP previously agreed to integrate Altmetric badges to scholarly content obtained via Reprints Desk's award-winning research retrieval platform Article Galaxy. Altmetric is a foremost research metrics provider. 

Reprints Desk signed separate reseller agreements with Ritme and Alfasoft to deliver new tools and services. These tools and services address the complete range of knowledge acquisition and information management requirements of researchers in scientific, technical, as well as medical (STM) fields.

Research Solutions’ wholly-owned subsidiary Reprints Desk and technology company Digital Science have formed an agreement bringing together the power of two research tools: Article Galaxy and Dimensions. Reprints Desk's award-winning Article Galaxy research platform provides customers with fast, reliable, and personalized access to full-text scientific literature and intelligent data insights. Digital Science's new research and discovery database, Dimensions, integrates more than 135 million publications, grants, clinical trials, and patents.

Last week, Research Solutions and its subsidiary Reprints Desk announced the launch of the Article Galaxy Gadget Store. Powered by Reprints Desk's Article Galaxy research platform, the Gadget Store provides access to a first of its type library of science applications, named Gadgets, designed for research and scientific experimentation.

Mr. Peter Derycz, Research Solutions’ President and Chief Executive Officer, said, "We created the Gadget Store to help researchers improve discovery and save time. From document delivery to reference management to lab tools, our customers can choose the Gadgets they need for the specific task at hand. The Gadget Store lets scientists keep all their research in one place—with easy access to scientific content and data—without ever leaving their workflow. As a result, our customers report time savings of more than 50 percent."

Research Solutions, Inc. (RSSS), closed Friday's trading session at $2.40, up 12.68%, on 3,982 volume with 4 trades. The average volume for the last 3 months is 1,995 and the stock's 52-week low/high is $1.50/$2.70.


Maple Gold Mines Ltd. (MGMLF)

Jet Life Penny Stocks, Junior Mining Network, Dividend Investor, Wallet Investor, InvestorsHub, GuruFocus, Investors Hangout, Wall Street Nation, OTC Markets, Stockwatch, Stockhouse, 4-Traders, MarketWatch, TradingView, and Barchart reported beforehand on Maple Gold Mines Ltd. (MGMLF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Maple Gold Mines Ltd. is an exploration company focused on advancing a district-scale gold project in one of the world’s premier mining jurisdictions. The Company’s 377 km2 Douay Gold Project is within the prolific Abitibi Greenstone Belt in northern Quebec. OTCQB-listed, Maple Gold Mines has its management office in Toronto, Ontario. The Company formerly went by the name Aurvista Gold Corporation. It changed its name to Maple Gold Mines Ltd. in November 2017.

The Douay Gold Project has first-rate infrastructure with large operating mines within 150 kms. There is significant resource expansion and exploration upside at the Douay Gold Project. The Project has an established gold resource that remains open in numerous directions. Maple Gold is centering on expanding the known resource areas and testing new discovery targets within its 55 km of strike along the Casa Berardi Deformation Zone.

The updated resource estimate (NI 43-101 Technical Report - March 2018) successfully converted a significant proportion of Inferred to the Indicated Resource category, at Douay West and Porphyry Zones. Resources at Douay now stand at 2.76 million ounces Inferred plus 0.48 million ounces Indicated.

Last month, Maple Gold Mines announced it added $1.9M to its treasury after receiving its full 2017 tax credit refund from Revenu Québec. The winter 2019 drill program is testing refined higher-grade targets generated from recently reported 3D modeling work. Mapping and gold deportment work will continue through summer 2019.

A new resource update is expected in late Q1. In addition, Maple Gold plans to start a Preliminary Economic Assessment (PEA) in late 2019. It has designed a 10,000 meter program. The Company plans to drill a minimum of 5,000 meters this winter focused on different targets.

Mr. Matthew Hornor, Maple Gold's President and Chief Executive Officer, said: "We have ranked and prioritized all of our drill targets and with more than $4M in the treasury we are now in position to test top priority drill targets, while concurrently working with RPA on our new resource estimate for Douay."

Maple Gold Mines Ltd. (MGMLF), closed Friday's trading session at $0.065, up 20.37%, on 82,850 volume with 10 trades. The average volume for the last 3 months is 62,656 and the stock's 52-week low/high is $0.054/$0.159.


Golden Leaf Holdings Ltd. (GLDFF)

Stockhouse, Silicon Investor, Market Screener, Marketwired, Tip Ranks, The Seed Investor, InvestorX, Pot Stock News, InvestorsHub, Daily Marijuana Observer, Simply Wall St, MarketWatch, and Infront Analytics reported previously on Golden Leaf Holdings Ltd. (GLDFF),  and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Golden Leaf Holdings Ltd. is one of the largest cannabis oil and solution providers in North America. In addition, it is a leading cannabis business in Oregon. Golden Leaf has expertise in extracting, refining, marketing, and selling cannabis oil. Golden Leaf Holdings has its corporate office in Toronto, Ontario. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Golden Leaf Holdings is a foremost cannabis products company built around recognized brands. The Company has operations in many jurisdictions including Oregon, Nevada and Canada. It cultivates, extracts, manufactures and distributes its products through its branded Chalice Farms retail dispensaries and via third party dispensaries.

Golden Leaf’s Canadian subsidiary is Medical Marijuana Group (MMG).  MMG's genetic portfolio includes a strain that holds the highest CBD concentrations in Canada.  MMG was granted a cultivation license from Health Canada in November of 2017 for its state-of-the-art grow facility in Ontario. It began cultivation activities in early 2018.

Golden Leaf’s brands include Golden, Left Coast Connection, and Chalice Farms. Since opening in 2014, Chalice Farms has served the greater Portland, Oregon community with its chain of dispensaries selling its line of premium edibles.

Golden Leaf announced this past November the launch of its edible product line of cannabis infused fruit chews to the Nevada market under the “Golden” brand. In Nevada, Golden Leaf sells a range of ethanol-extract distillate, oils and distillate blends under the Golden Private Stash, RSO-Go and Jackpot brands. Its products now sell wholesale in about 40 percent of dispensaries in Nevada.

Last month, Golden Leaf Holdings announced the appointment of Ms. Karyn O. Barsa as its new Chief Financial Officer (CFO), effective February 4, 2019. In her role as CFO, Ms. Barsa will lead the Company’s financial operations. She will be responsible for managing liquidity, balance sheet risk, and capital market transactions to ensure Golden Leaf remains well positioned to capitalize on growth opportunities. She will report directly to Mr. William Kulczycki, Chief Executive Officer and President of Golden Leaf Holdings.

Golden Leaf Holdings Ltd. (GLDFF), closed Friday's trading session at $0.0731, down 5.36%, on 277,441 volume with 54 trades. The average volume for the last 3 months is 385,806 and the stock's 52-week low/high is $0.064/$0.24.


Azucar Minerals Ltd. (AXDDF)

Tip Ranks, Streetwise Reports, GuruFocus, Morningstar, Investorx, Stockwatch, The Street, Penny Stock Hub, Barchart, Dividend Investor, Stockhouse, MarketWatch, InvestorsHub, Market Screener, 4-Traders, and Interactive Brokers reported earlier on Azucar Minerals Ltd. (AXDDF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Azucar Minerals Ltd. is an exploration company with a mandate to thoroughly explore the El Cobre project in Veracruz, Mexico. The Company was formerly known as Almadex Minerals Limited. It changed its name to Azucar Minerals Ltd. in May of last year. Azucar Minerals has its corporate office in Vancouver, British Columbia. The Company lists on the OTC Markets’ OTCQX.

Azucar Minerals holds a 100 percent interest in the El Cobre project, subject to Net Smelter Returns (NSR) royalty interests, assuming production from the property exceeds 10,001 tonnes per day of ore, totaling 2.25 percent which can be reduced to 2.0 percent through the payment of US$3.0 million.

The El Cobre project is a roughly 7,300 Ha property. It covers manifold gold-rich porphyry targets, as demonstrated by recent drilling. Azucar Minerals is fully permitted for drilling and funded for an active exploration campaign this year. El Cobre is 75 kilometers northwest of Veracruz city.

The El Cobre project is road accessible. It is situated in an area of first-rate infrastructure, close to a power plant, highways and rail systems. The project has four copper-gold porphyry targets - Encinal, El Porvenir, Norte, and Villa Rica. The porphyries are defined by distinct copper-gold soil anomalies, discrete positive magnetic features, and an extensive shallow IP chargeability anomaly.

In late February, Azucar Minerals announced that it hit 18.00 M of 0.51 g/t Au and 0.43% Cu at the Villa Rica Target, El Cobre Project, Mexico. The Company announced results from its continuing drilling program at the El Cobre porphyry copper-gold project in Veracruz State. Drilling is now taking place at the Villa Rica target, the Norte zone and in the Porvenir/Encinal area.

The results reported are from the Villa Rica area, a large (approximately 2.5 by 1 km) altered area defined by high magnetics responses with local zones of elevated copper, gold and molybdenum in soil. Hole EC-18-052 and 054 were drilled underneath the earlier announced hole EC-17-037.

Both EC-18-052 and 54 hit porphyry mineralization (EC-18-052 hit 18.00 meters that averaged 0.51 g/t gold and 0.42% copper). The intercepts in the three holes suggest that the mineralized intrusive has been clipped and the drilling has not cut across the potential porphyry body so far. More drilling is taking place in the Villa Rica area based on these results.

Azucar Minerals Ltd. (AXDDF), closed Friday's trading session at $0.2045, up 7.41%, on 16,937 volume with 6 trades. The average volume for the last 3 months is 34,834 and the stock's 52-week low/high is $0.189/$0.9297.


Gratitude Health, Inc. (GRTD)

Penny Stock Hub, Dividend Investor, Morningstar, Stockhouse, GuruFocus, Cannabis Daily, Zacks, Wallet Investor, Simply Wall St, MarketWatch, Investors Hangout, InvestorsHub, Trading View, The Street, Barchart, and 4-Traders reported previously on Gratitude Health, Inc. (GRTD), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Gratitude Health, Inc. manufactures, sells, and markets functional ready-to-drink (RTD) beverages under the Gratitude brand. The Company’s Founders, Mr. Roy Warren and Mr. Andy Schamisso, are beverage veterans with more than three decades of experience in the industry. Gratitude Health was formed to manufacture healthy, unique, and certified-organic beverages for a consumer market interested in healthy aging. Established in 2017, Gratitude Health is based in North Palm Beach, Florida and lists on the OTCQB.

Gratitude Health announced last year that it entered into a definitive exchange and spinoff agreement with Vapir Enterprises, Inc., previously traded under the symbol VAPI. The combination facilitated Gratitude Health, Inc. to become a publicly traded company. With the agreement, Vapir Management retains its operations, intellectual property (IP), assets, and liabilities. It will continue as a separate operating entity and will not be involved in the beverage business.  Vapir is a developer and manufacturer of vaporization devices.

Gratitude Health offers flavored and unsweetened RTD teas. The Company’s alternative food and beverage options are nutrient rich. They feature reduced or eliminated carbohydrate and sugar levels. Moreover, they are full of anti-oxidants and organic ingredients. Each bottle contains no more than 45 calories. Gratitude Health’s 16 oz proprietary bottles feature collectible debossed designs intended to be reused and repurposed.

The Company pan-roasts its tea by hand. Its tea flavors include Dragon Well Green Tea Peach; Dragon Well Green Tea Mint; Dragon Well Green Tea Wildberry; Dragon Well Green Tea Blood Orange; and Dragon Well Green Tea Original. Dragon Well tea (culturally known as "Longjing") comes from the pristine, certified-organic fields of Hangzhou China. Dragon Well tea has the distinction of being named "The Tea of Emperors". It is the most popular in The People’s Republic of China (PRC).

Gratitude Health’s next proprietary product line will further advance the Company mantra of providing healthy, functional drink offerings by specifically targeting what Gratitude call’s “nutrition for  aging.” The forthcoming line of innovative, nutrition-rich and balanced meal-replacement drinks will provide a scientifically proven weapon to battle this disease. Therefore, Gratitude Health has contracted with a world-class scientific advisory body to develop ketogenically balanced macro-nutrient delivery. The Company is nearing the end of this formulation and development process.

Recently, Gratitude Health announced its plans to launch KetoRefuel™. This is the world’s first Ready-to-Drink (RTD) line of ketogenic meal-replacement shakes. This product is targeted for launch in Q2 2019. The first drinks to launch in the KetoRefuel lineup will be Chocolate, Vanilla and Caffeinated Mocha Ketogenic Meal-Replacement Shakes in 16.9 oz, shelf-stable Tetra Pak® containers that are re-sealable and have been consumer-tested for user-friendliness.

Gratitude Health, Inc. (GRTD), closed Friday's trading session at $0.051, up 2.20%, on 300 volume with 2 trades. The average volume for the last 3 months is 23,775 and the stock's 52-week low/high is $0.01/$0.15.


Integra Resources Corp. (IRRZF)

High Rising Stocks, Stockhouse, Junior Mining Network, The Hot Penny Stocks, Barchart, The Prospector News, Stockwolf, Trading View, Penny Stock Hub, Investing News Alerts, GuruFocus, MarketWatch, InvestorsHub, Dividend Investors, and Streetwise Reports reported earlier on Integra Resources Corp. (IRRZF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Integra Resources Corp. engages in the acquisition, exploration and development of mineral properties in the Americas. Its principal focus is the advancement of its DeLamar Project. The OTCQX-listed Company previously went by the name Mag Copper Limited. It changed its corporate name to Integra Resources Corp. in August of 2017. A development-stage enterprise, Integra Resources is based in Vancouver, British Columbia.

The Company’s DeLamar Project consists of the neighboring DeLamar and Florida Mountain Gold and Silver Deposits in the core of the historic Owyhee County mining district in southwestern Idaho. The DeLamar Project consists of approximately 5,300 acres of patented and unpatented claims, and a further 4,100 acres of leased lands with roughly 1,575 historic drill holes and 145,940 meters of drilling outlined in historic databases. Integra Resources began a $10 million drill program at DeLamar last year.

Integra Resources has acquired a 100 percent interest in the Empire Claim Group for USD $1.6 million. The Empire Claim Group encompasses more than 95 percent of the past producing Florida Mountain gold-silver Project. Integra Resources’ interest is free of all royalties and other types of financial encumbrances. With this agreement, Integra Resources acquired 36 patented mining claims totaling about 440 acres.

This month, Integra Resources announced the acquisition of a highly prospective trend of multiple epithermal centers 6 km to the northwest of the DeLamar Project, a trend now referred to as the Black Sheep District. The District was identified in part during site visits and research by renowned epithermal geologists Dr. Jeff Hedenquist and Dr. Richard Sillitoe. Dr. Sillitoe and Dr. Hedenquist, along with Integra Resources’ exploration team, mapped the area and interpreted the District to have undergone very limited erosion since the mid-Miocene mineralization event.

This suggests that the productive zone of mineralization is potentially about 200 m beneath the surface. Minimal historical exploration did encounter gold-silver in Black Sheep. However, historic drilling was shallow, less than 100 m vertical on average. In addition, historic drilling did not enter the theorized productive zone.

Mr. George Salamis, President and Chief Executive Officer of Integra Resources, said, “We are excited by the discovery of gold-silver surface showings at Black Sheep. The Black Sheep District, which extends for 6 km to the northwest, includes multiple prospects with typical high-level style epithermal mineralization associated with gold and silver deposits. Extensive soil geochemical anomalies in the District have been mapped with multiple signatures exceeding 1.5 km in length.”

Integra Resources Corp. (IRRZF), closed Friday's trading session at $0.61, up 4.69%, on 17,250 volume with 13 trades. The average volume for the last 3 months is 23,938 and the stock's 52-week low/high is $0.443/$0.738.


The QualityStocks Company Corner

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex Inc. (NASDAQ:GNPX) announces the availability of a NetworkNewsAudio publication titled, “Biotechs That Successfully Combat Cancer Could See Blockbuster Returns.” To hear the NetworkNewsWire Audio version, visit: To read the full editorial, visit:

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed the day's trading session at $1.62, up 1.31%, on 29,603 volume with 29,603 trades. The average volume for the last 3 months is 48,757 and the stock's 52-week low/high is $0.95/$11.42.

Recent News


Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands (CSE: SUN) (OTCQB: WLDFF) was recently highlighted in an article authored by Michelle Janikian on titled ‘10 Best CBD Oils and CBD Products on the Market’. The kit includes CBD vape pens, capsules, soap, and a cool stick that was designed to deliver quick and convenient pain relief.  Wildflower’s CBD+ Wellness Starter Kit is available for purchase at To view the full article, visit: Also today, the company was highlighted in the 420 with CNW by CannabisNewsWire. In a 7-0 emphatic decision, the Supreme Court of Arizona has quashed a ruling by the Court of Appeal to the effect that marijuana concentrates, such as hashish, were not included in the law which legalized medical marijuana in the state.

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed the day's trading session at $0.5049, up 4.34%, on 6,865 volume with 9 trades. The average volume for the last 3 months is 22,795 and the stock's 52-week low/high is $0.009/$1.129.

Recent News


Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: INNPF).

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P) was announced today by Virtual Investor Conferences and KCSA Strategic Communications, as on the agenda of the upcoming Cannabis Industry Virtual lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 8:45 AM ET, with the first live webcast at 9:00 AM ET, on Tuesday, June 4.

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."


While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: INNPF), closed the day's trading session at $0.48, up 4.76%, on 74,626 volume with 40 trades. The average volume for the last 3 months is 265,702 and the stock's 52-week low/high is $0.392/$0.791.

Recent News

chart (CIIX)

The QualityStocks Daily Newsletter would like to spotlight (CIIX). (OTCQB: CIIX) has announced that Alex Hamilton, CFO of the company’s wholly owned foreign enterprise CBD Biotechnology Co. Ltd., will be presenting at the 9th Annual LD Micro Invitational taking place at the Luxe Sunset in Bel-Air, California June 4–5, 2019. To view the full press release, visit:

Founded in 1999, (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website,, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site,, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. (CIIX), closed the day's trading session at $0.455, up 2.25%, on 23,261 volume with 23 trades. The average volume for the last 3 months is 58,007 and the stock's 52-week low/high is $0.365/$1.25.

Recent News


Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF).

Petroteq Energy (TSX.V: PQE) (OTC: PQEFF), an oil and gas industry technology innovator, recently closed a private placement resulting in gross proceeds of $985,950. To view the full article, visit:

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil sands exploration and production on mineral leases in Vernal, Utah, and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 2,500-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Clean Oil Recovery Technology (CORT) System.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ. PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy Chairman Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry.

“API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy Inc. (PQEFF), closed the day's trading session at $0.29964, up 7.01%, on 292,531 volume with 84 trades. The average volume for the last 3 months is 196,946 and the stock's 52-week low/high is $0.242/$1.43.

Recent News


Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI)

The QualityStocks Daily Newsletter would like to spotlight Organigram Holdings Inc. (OGI).

Organigram Holdings Inc. (TSXV: OGI) (NASDAQ: OGI), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce its recreational cannabis plants and growing processes have been certified organic with Pro-Cert Organic Systems Ltd. ("Pro-Cert"). Also today, the company was pleased to announce that it has closed its previously announced credit facility with Bank of Montreal ("BMO") as lead arranger and agent as well as a syndicate including three other lenders.  The facility consists of a $115 million term loan and a $25 million revolving credit facility (together, the "Facilities"), both of which mature in May 2022.  Included in the facility is an uncommitted option to increase the Facilities by an incremental $35 million to a total of $175 million, subject to agreement by BMO and satisfaction of certain legal and business conditions.

Organigram Holdings Inc. (TSX.V: OGI) (NASDAQ: OGI) is the parent company of Organigram Inc., an original and leading Canadian licensed producer ("LP") of premium, quality cannabis and extract-based products. Founded in 2013 and headquartered in Moncton, New Brunswick, Canada, Organigram is focused on producing the highest-quality indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the company's global footprint.?

Organigram delivers industry-leading yields and maximizes cannabis production at the lowest cultivation cost among other Canadian licensed producers. Organigram's high-tech facilities utilize an efficient, state-of-the-art mechanical room that includes both ethanol and CO2 extraction methods.

The company first began as a medical cannabis provider producing 5,000 kg/year (11,000 lbs) of 100 percent organic cannabis grown in pre-fabricated grow pods. Within two years, Organigram increased production to 36,000 kg/year (70,000 lbs) by utilizing an inventive, indoor 3-tier growing system. The company's pharmaceutical grade, state-of-the-art facility currently houses over 45,000 flowering plants growing at any one time.

Organigram's head office, production facility and research & development program are located on the company's 14-acre campus that houses several buildings and a 40-megawatt substation. Leading the way with a proprietary software system that acts as the nervous system of the entire organization, Organigram's team employs a data-driven decision-making process that ensures efficiency and top yields. Numerous design and automation improvements include an ergonomically friendly grow room design, automatic potting machines and automated packaging lines, and larger propagation rooms with advanced environmental systems.

Organigram's fully funded Phase 4 expansion is underway which, when complete by fall of 2019, will bring production capacity of high-quality premium cannabis to 113,000 kg/year (249,000 lbs). The Company has also invested in Hyasynth, a Montreal-based biotechnology company and leader in the field of cannabinoid science and biosynthesis. Hyasynth has developed a disruptive technology using patented enzymes to naturally produce cannabinoids without growing the cannabis plant. This process has the potential to create a global supply of pure cannabinoids at a fraction of the cost of traditional cultivation.

Organigram expects to double its workforce within the year to accommodate increasing growth as the facility expands to 480,000 square feet of production space at full buildout. In September 2017, Organigram signed the first ever recreational cannabis supply agreement in Canada with the Province of New Brunswick. Since then, Organigram has signed similar supply agreements with nine out of 10 provinces, has already exported product out of Canada, and is currently working with German medical cannabis provider, Alpha-cannabis, and Serbia-based Eviana Health Corp. (CSE: EHC), a hemp farm and processing facility.

Organigram has entered into an exclusive consulting agreement with The Green Solution (TGS), a proven market leader based in Denver, Colorado, with 16 retail locations, for development of commercial scale extraction and product processing, along with derivative product development (edibles, vaporizable products and beverage product mixes). Organigram's partnership with Canada's Smartest Kitchen, a leader in food product development, will expand and develop the Company's edibles R&D program and creation of premium chocolate products. Organigram has also signed a multi-year extraction contract with Valens GroWorks Corp. for Valens to produce extract concentrate for oils and derivative products.

Organigram is well-positioned in the cannabis space with several adult-use recreational product lines. These include:

  • Trailblazer offers a consistent value with a pre-roll, milled format
  • Trailer Park Buds provides niche equity for mainstream users that seek pre-rolls
  • Ankr Organics offers premium, organic pre-roll and oils
  • Edison Cannabis Co. delivers robust, high THC in a whole flower, pre-roll and oil produced from premium sorted flowers
  • Edison Cannabis Co. Reserve offers an ultra-premium, large whole flower that is craft cured and hand trimmed

Experienced Executive Team

  • CEO Gregory Engel has more than 30 years of experience in the pharmaceutical industry with over three years of experience as a CEO for a cannabis company.
  • Jeff Purcell, senior vice president of operations, has 25 years of experience in operations for companies such as Ganong Chocolates and McCain Foods.
  • Tim Emberg, senior vice president of sales and commercial operations, has 20 years of experience in pharmaceutical sales and marketing in the OTC and consumer packed good industry.
  • Guillermo Delmonte, president of international operations, brings experience in leading a global cannabis company and worked for 2.5 years as CEO of ICC Labs Inc. in Uruguay.
  • Larry Rogers, vice president of international operations, has held roles for Organigram since 2014 including being a member of the board of directors, chief operating officer and vice president/business development.
  • Paolo DeLuca, chief financial officer, has 20 years of diversified financial business experience including with West Face Capital and TD Securities.
  • Ray Gracewood, chief commercial officer, has 15 years of experience in the marketing space and is a previous senior director of sales and marketing for Moosehead Breweries Ltd.
  • Michael Tripp, chief legal officer, worked for private practices at respected business law firms in Moncton and Toronto where he acted on over $3 billion in transactions.

Organigram Holdings Inc. (NASDAQ: OGI), closed the day's trading session at $7.24, off by 4.11%, on 1,042,971 volume with 4,138 trades. The average volume for the last 3 months is 1,323,071 and the stock's 52-week low/high is $2.97/$8.44.

Recent News


The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF)

The QualityStocks Daily Newsletter would like to spotlight The Flowr Corporation (FLWR).

The Flowr Corporation (TSXV: FLWR; OTC: FLWPF) (“Flowr” or the “Company”) today announced the Company will participate at Piper Jaffray’s 39th Annual Consumer Marketplace Conference, being held on Thursday, June 6, 2019, at The Pierre New York in New York City.

The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF), a Health Canada Licensed Producer (LP) of cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR), is an emerging Canadian cannabis leader founded by Medreleaf co-founder Tom Flow and a team of industry pioneers, successful start-up executives and top industry scientists. Flowr’s purpose-built cultivation facilities may be the most advanced in the industry, consistently generating high crop yields, delivering premium and ultra-premium cannabis products, and maximizing return on investment. The company also may be an R&D leader as it was selected by the Hawthorne Gardening Division of The Scotts Miracle-Gro Company as its exclusive Canadian cannabis R&D partner.

Flowr’s flagship facility, an 84,000-square-foot campus on seven acres in Kelowna, British Columbia, is engineered to grow premium cannabis in rooms that meet pharmaceutical industry production standards for cleanliness. This, along with exacting protocols designed by the Flowr team, enables Flowr to grow cannabis that meets Health Canada’s stringent standards without treating it with the taste- and smell-killing gamma irradiation that most other producers have to use to clean their product. Irradiating the plant – a process similar to pasteurizing food – impairs many of the important terpenes that provide the positive effects, flavors and scents of cannabis while strengthening unpleasant terpenes. Flowr’s products may deliver a better user experience, thus commanding premium prices.

Flowr’s cultivation facilities, built with proprietary, patent-pending systems, are designed to deliver yields targeted at 450 grams per square foot by the end of 2022, which is three times more efficient than the industry average of approximately 150 grams per square foot. By optimizing yield, the Company may produce significantly more cannabis flower on a smaller footprint than other producers, thus generating far high revenue per square foot and keeping costs much lower, leading to higher margins. The Kelowna facility is presently 20 percent operational with the remaining 80 percent slated to come online by early 2019. It is expected to produce up to 14,000 kg of premium, non-irradiated cannabis flower in 2019. With further enhanced yields and planned expansion of production facilities on the campus, Flowr will reach a total capacity of 60,000 kg annually in 2022.

Leading Flowr’s cultivation program is industry pioneer, company co-founder and Flowr president Tom Flow. Flow is widely recognized for his cannabis thought leadership and expertise building and operating cannabis cultivation facilities. Flow also co-founded MedReleaf and designed, built and set up SOPs for their flagship Marcum cultivation facility. Marcum has continued to be perhaps the most productive facility in the country prior to the Flowr flagship facility. Long one of Canada’s most efficient and profitable LPs, MedReleaf was acquired by Aurora for approximately C$3 billion. Flow and his team have designed and built a total of 17 cultivation facilities and secured three producer’s licenses under various Canadian regulatory regimes.

In March 2018, Flowr and the Hawthorne Gardening Division of The Scotts Miracle-Gro Company – a world leader in lawn and garden products – announced an exclusive strategic R&D alliance. After evaluating numerous Canadian LPs, Hawthorne chose to partner with Flowr based on the experience and expertise of the company’s cultivation and R&D teams and the company’s advanced growing capabilities.

Hawthorne will fund the construction of a 50,000-square-foot R&D facility that is integrated into Flowr’s Kelowna campus. This facility is North America’s first dedicated cannabis R&D facility focused on advancing cultivation techniques and systems. The facility will support researchers from both organizations and combine laboratories, indoor and greenhouse grow suites, training areas and genetics breeding areas in a single building. It is expected to open in early 2019. In addition to helping Flowr maintain its competitive advantage in cultivation, the company’s R&D program will keep it on the cutting edge of cannabis innovation.

Flowr is entering the market with three different brands to meet the growing demand for premium, non-irradiated cannabis in the medicinal and adult use markets:

  • FlowrRx, featuring premium quality medicinal cannabis that enables patients to live better, fuller lives. A dedicated Client Services team will provide patients with personalized support while an R&D team develops innovative flower strains and premium products targeted to specific conditions. Patient well-being is considered at every stage of the process – from genetic selection to harvest, trimming and curing techniques. FlowrRx and its team of passionate scientists and leading cultivation specialists are dedicated to advancing the scientific understanding of cannabis.
  • Flowr is the company’s premium recreational adult-use brand featuring an active, West Coast-inspired lifestyle for the cannabis connoisseur and enthusiast market. Through the continuous innovation of procedures and practices, Flowr’s talented team of experts is crafting premium products that deliver unparalleled experiences.
  • Ace Valley, an exclusive partnership with top-selling Ontario craft beer company Ace Hill, will bring Flowr’s premium product to the millennial and casual adult-use markets under the Ace Valley brand.

Flowr recently signed a Memorandum of Understanding with the British Columbia Liquor Distribution Branch, the province’s sole legal wholesaler of non-medical cannabis, to supply premium and ultra-premium flower to the province’s retail outlets. The company has agreements with several major medical distributors and is in discussions about retail distribution with additional provinces where it believes it can obtain prices commensurate with the quality of the Flowr products. The company is also evaluating other market opportunities including export.

Flowr is poised to become the pre-eminent indoor premium cannabis grower in Canada and one of the country’s top five LPs. The company’s focus on yield, quality and price point and its team’s ability to grow at scale should drive high margins, significant growth and strong return on investment.

The Flowr Corporation (TSX.V: FLWR), closed the day's trading session at $6.80, off by 3.95%, on 123,044 volume with 361 trades. The average volume for the last 3 months is 285,298 and the stock's 52-week low/high is $2.74/$8.42.

Recent News


Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Youngevity International, Inc. (NASDAQ: YGYI) was featured today in the 420 with CNW by CannabisNewsWire. In a 7-0 emphatic decision, the Supreme Court of Arizona has quashed a ruling by the Court of Appeal to the effect that marijuana concentrates, such as hashish, were not included in the law which legalized medical marijuana in the state.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed the day's trading session at $5.53, off by 5.47%, on 74,220 volume with 541 trades. The average volume for the last 3 months is 106,556 and the stock's 52-week low/high is $3.167/$16.25.

Recent News


Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

PLUS Products Inc. (CSE:PLUS) (OTCQB:PLPRF), one of California’s top edibles brand and manufacturer by market share according to BDS Analytics, today announced CEO and Co-Founder Jake Heimark will be a panelist at the Eight Capital & Cassels Brock – State of the Union: American Cannabis Forum on Tuesday June 4, 2019 at 1:00pm ET at the Shangri-La Hotel in Toronto. The theme of the panel Jake will be participating in is “Creating Winning Brands”.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed the day's trading session at $3.37, off by 2.32%, on 58,709 volume with 126 trades. The average volume for the last 3 months is 77,101 and the stock's 52-week low/high is $2.81/$6.01.

Recent News


Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces the availability of a CannabisNewsAudio Broadcast titled, “Disruptive CBD Delivery Technology Could Revolutionize World of Cannabis Consumer Products, Edibles.” To hear the CannabisNewsAudio version, visit: To read the full editorial, visit:

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $0.922475, off by 1.92%, on 62,234 volume with 48 trades. The average volume for the last 3 months is 106,495 and the stock's 52-week low/high is $0.75/$2.43.

Recent News


Sproutly Canada, Inc. (OTCQB: SRUTF) (CSE: SPR) (FRA: 38G)

The QualityStocks Daily Newsletter would like to spotlight Sproutly Canada, Inc. (SRUTF).

Sproutly Canada (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) is on a mission to gain exposure through presentations of its groundbreaking, proprietary Aqueous Phytorecovery Process (“APP”) technological platform at several significant cannabis conferences held throughout the United States and Canada. To view the full article, visit:

Sproutly Canada, Inc. (OTCQB: SRUTF) (TSX.V: SPR) (FRA: 38G) is developing and bringing to market cannabis consumer products with a focus on beverages. The company’s core mission is to become the leading supplier of water-soluble cannabis solutions and bio-natural oils for brands in the emerging cannabis beverage and edibles market.

To make this happen, Sproutly acquired Infusion Biosciences to bring to market a patent-pending Aqueous Phytorecovery Process (APP) technology, a fundamental paradigm shift within the cannabis industry. Replacing traditional water-compatible solutions with true natural water solubility improves the body’s ability to utilize cannabinoids, making the effect of the cannabis almost immediate.

This revolutionary process doesn’t alter the cannabis compounds and provides an onset time and offset time that mimics the same effects as inhaled marijuana. That means consumers may feel effects in five minutes or less and be free from the desired effect in approximately 90 minutes—a vastly different ingestion pattern than current methods. In addition, the water-based cannabinoids can be mixed with other liquids and stay dissolved in those liquids. The application of water-soluble cannabis infusions has potential to be widespread in both medicinal and recreational cannabis sectors, giving Sproutly a distinctive edge in a market with untapped potential.

Sproutly’s business model is focused on processing rather than cultivating, which means its success is not constrained to growing its own cannabis. The company does own a Toronto-based, ACMPR-licensed facility designed and built with a focus on cultivating pharmaceutical-grade cannabis to produce and formulate the first natural, truly water-soluble cannabis solution. Its water-soluble ingredients and bio-natural oils will deliver revolutionary brands to international markets that are searching for well-defined commercial products.

Sproutly’s entrance in the cannabis market is perfectly timed as cannabis is moving towards mainstream acceptance. Potential users are, however, interested in consuming cannabis products as drinks and using it as oils rather than smoking. The potential cannabis beverage market is staggering, and with Sproutly owning the exclusive rights to APP technology in Canada, Australia, Jamaica, Israel and the entire European Union, the company is looking at significant international expansion opportunities.

Sproutly plans to capitalize on these international opportunities by executing on partnerships with local and globally established consumer brands to leverage their existing customer bases, expand brand loyalty, and assist with marketing and support distribution networks to deliver scientific breakthroughs with speed and efficiency?worldwide.


Sproutly believes that talent drives growth. The company is committed to bringing together the best and brightest minds in the cannabis space to help with their mission to disrupt the global beverage and consumables market.

President, CEO and Director Keith Dolo recently served for more than 13 years with Robert Half, an S&P 500, NYSE-listed company. At Robert Half, Dolo held the position of vice president for more than eight years, as well as other senior roles in both operations and sales. He also sits on an advisory committee and a board position for two nonprofits in Vancouver, BC.

Chief Science Officer and Director Dr. Arup Sent has more than 35 years of experience in research and executive management at biotechnology and pharmaceutical companies. He was awarded a PhD in biochemistry from Princeton University and is a former faculty member at the National Cancer Institute and Scripps Research Institute. Sen is the inventor on five U.S. patents and numerous international patents and patent-pending applications.

Chief Financial Officer Craig Loverock is a chartered professional accountant with over 20 years of experience in accounting and finance roles in Canada, the United States and the United Kingdom. He has extensive expertise in public company reporting and transactional experience, having served as the senior financial advisor to the chairman at Magna International and acting as chief compliance officer and CFO for a private equity firm.

Head Grower Frank Han has over 12 years of experience in the horticulture industry. A previous master grower in a large commercial facility, Han has impressive expertise in all growing methods, techniques and procedures. He brings with him a wealth of knowledge in cloning, nutrient and overall plant management. Han will be in charge of the production team at Sproutly’s Toronto Herbal Remedies facility.

Sproutly Canada, Inc. (OTCQB: SRUTF), closed the day's trading session at $0.5791, off by 0.46%, on 393,962 volume with 185 trades. The average volume for the last 3 months is 791,063 and the stock's 52-week low/high is $0.189/$1.875.

Recent News


Geyser Brands Inc. (TSX.V: GYSR)

The QualityStocks Daily Newsletter would like to spotlight Geyser Brands Inc. (TSX.V: GYSR).

Vancouver-based Geyser Brands (TSX.V: GYSR) is anticipating a yield increase of 200% for its third harvest following the recent completion of its second harvest. Presently, the company is planning to expand its reach in the industry. To view the full article, visit:

Geyser Brands Inc. (TSX.V: GYSR) is a consumer healthcare company that builds and markets some of the world's most loved cannabis products and brands in the nutraceutical, cosmetics, food and beverage and pet sectors. Using its proprietary nanotechnology formulation, the company delivers creams, beverages, baked goods and tincture formulations with superior bioavailability and water solubility.

NanoFusion Technology

The efficacy of most hemp?products is restricted as the insoluble nature of the molecules prevents most of the product from permeating the skin or entering the body system. Geyser Brands solves this insolubility problem with an advanced delivery system that quickly and efficiently transports therapeutic agents directly to the bloodstream for maximum absorbency.

Made with all-natural materials, NanoFusion technology offers an array of advantages: enhances penetration for deeper skin penetration; improves the transport of active ingredients for site-specific targeting; delivers active ingredients across cell membranes for release within the cell; provides longer shelf-life and stability of molecules.


Geyser Brands operates a 7,000-square-foot facility in Port Coquitlam, British Columbia, where its initial cannabis cultivation generated the first revenues out of the company's cultivation license granted in October 2018. Geyser Brands is approved as a licensed producer in compliance with Health Canada standards, which allows the company to pursue its processing and sales license. Obtaining this license will enable the company to extend its products and brands into the regulated Canadian cannabis market and directly to the consumer medical market.

Geyser Brands's integrated production chain and formulation lab develops innovative products using high-quality hemp and CBD for healthy lifestyle brands while its R&D lab produces product formulations designed to enhance bio-availability of hemp and CBD and shelf stability while maintaining all-natural ingredients and ensuring premium quality.

Geyser Brands will continue to seek opportunities to invest into the research and development of unique high-quality proprietary strains and technologies that target specific health-related conditions such as pain and inflammation reduction, insomnia, digestive issues and other commonly known ailments.

Growing Portfolio

Among the brand formulations in Geyser Brand's portfolio are:

  • Apothecary all-natural Hemp Terpene Pain Cream with optimal skin permeation
  • Prohibition Cold Brew Mocha designed with water soluble hemp molecules
  • Apothecary health products created to deliver fast-acting and high bioavailability in a spray formulation
  • Baked hemp infused pet products, designed to alleviate anxiety and pain, created with NanoFusion for dosage control

Management Team

Since 2014, Geyser Brands' CEO and Co-Founder Andreas Thatcher has been a principal at Rhizome Group, an entertainment company focused on building media IP through creative and market development. He previously was a founding partner at Rhizome Capital LLC, a U.S.-based media?investment?company specializing in marketing and distribution financing, and worked in the Investment Banking industry in?London and Toronto. Thatcher holds a master's degree in economics.

CFO Barry McKnight obtained his bachelor's degree from the University of British Columbia and is a Chartered Professional Accountant and?Certified Management Accountant registered in British Columbia. McKnight has over 20 years of experience as the principal of Barry D. McKnight Inc. He formerly was also a director of Indigo Sky Capital Corp. and has been the CFO and a director of the Company since 2016 and Corporate?Secretary of the Company since 2017.

Geyser Brands's Co-Founder Brad Kersch brings a strong business background with over 20 years of experience in?successful startups and working?with Fortune 500 companies. He spent his early years in the advertising and?marketing field and went on to form Hyperware, a clothing?company that sold branded clothing to retailers across Canada?before selling to clothing giant Ocean Pacific (OP). Kersch?became the president of Shoreline Studios, Canada's largest and?oldest?studio for film and TV. In 2014 he started Solace Management Group, a hemp product company focused on pet, cosmeceutical, and nutraceutical markets. As of February 2019, Geyser Brands signed a non-binding LOI to acquire Solace Management. Upon completing the proposed Solace acquisition, Geyser Brands intends to launch into the execution phase of its plan — to take its brands global through retail and digital direct-to-consumer experiences, launching its hemp-infused cannabis brands and products in the U.S., European Union, and Asia, and its CBD-infused line of products in jurisdictions where the therapeutic ingredient is legal.

Kuldip Gill, head of Geyser Brands' R&D program, has more than 35 years of experience in the cannabis industry. Gill built the largest manufacturing facility?in the lower mainland in Surrey, British Columbia, complete with R&D, analytical and quality control labs approved by both the FDA and Health Canada. He has to date created over 3,500 formulas, most notably Lakota pain relief gel. Gill's experience and proven track record is evident in the strongly marketable formulations he has developed and sold worldwide.

Geyser Brands Inc. (TSX.V: GYSR), closed the day's trading session at $0.56, off by 20.00%, on 42,553 volume with 16 trades. The average volume for the last 3 months is 8,370 and the stock's 52-week low/high is $0.55/$0.85.

Recent News


Spectrum Global Solutions, Inc. (SGSI)

The QualityStocks Daily Newsletter would like to spotlight Spectrum Global Solutions, Inc. (SGSI).

Spectrum Global Solutions Inc. (OTCQB: SGSI) is a foremost provider of comprehensive outsourced services and solutions for the deployment and maintenance of next-generation and legacy wireless and wireline telecommunication networks and infrastructure. The company has successfully executed on projects across the United States and globally. Based in Longwood, Florida, Spectrum is professionally registered in 49 states, three U.S. territories (Puerto Rico, the Unites States Virgin Islands and Guam) and six Canadian provinces in support of its clients (

Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

  • AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
  • ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
  • Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.


CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

Spectrum Global Solutions, Inc. (SGSI), closed the day's trading session at $0.135, off by 6.90%, on 19,501 volume with 3 trades. The average volume for the last 3 months is 98,076 and the stock's 52-week low/high is $0.071/$2.59.

Recent News


Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics Inc. (OTCQB: ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver proprietary, patent protected Electroceutical Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. As an innovative biotechnology company, Endonovo is harnessing bioelectricity to restore key electrochemical processes that initiate the anti-inflammatory and growth factor cascades necessary for healing to occur.

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s?targeted?pulsed electromagnetic field?(tPEMF)?transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone.?

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.


Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.


Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.?

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Endonovo Therapeutics Inc. (ENDV), closed the day's trading session at $0.01072, off by 9.92%, on 1,984,155 volume with 55 trades. The average volume for the last 3 months is 2,544,709 and the stock's 52-week low/high is $0.0089/$0.0661.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.